Histidine and immunotherapy response in colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how the amino acid histidine in your body might affect how well immunotherapy (a treatment that helps your immune system fight cancer) works for colorectal cancer. If you join, the results could help doctors better predict which patients may benefit from this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a confirmed diagnosis of colorectal cancer (or you have already been treated with PD-1 immunotherapy for it)
- Your blood pressure, diabetes, cholesterol, uric acid, or thyroid conditions are well controlled
- You do not have other serious gastrointestinal diseases (like inflammatory bowel disease or cirrhosis)
- You have had no other type of cancer, and your colorectal tumor is not a benign or neuroendocrine type
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking a histidine supplement (an amino acid building block) alongside standard colorectal cancer treatment helps your immune system fight the cancer better. Researchers want to see if this simple addition can improve outcomes for people with stage II or higher colorectal cancer.
This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.
This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
This study collects tissue and blood samples from people with colorectal, pancreatic, or bile duct cancer to learn how the immune system reacts to these tumors. The goal is to better understand cancer biology and potentially improve future treatments.
This study looks at how gut bacteria and immune activity differ in normal, pre-cancer, and cancer colon tissue. It may help researchers understand what changes in the body are linked to colon growth and how they could be targeted in the future.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.